Summary
Ecteinascidin 743 (Et 743), a natural product derived from the Caribbean tunicate Eteinascidia turbinata, is a potent antitumor agent currently in phase II clinical trials. Et 743 binds in the minor groove of DNA, forming covalent adducts by reacting with N2 of guanine. Although DNA is considered to be the macromolecular receptor for Et 743, the precise mechanism by which Et 743 exerts its remarkable antitumor activity has not yet been elucidated. The aim of this study is to provide a rationale for the antitumor activity of Et 743 by studying its fundamental interactions with DNA at the molecular level.
First, DNA structural distortions induced by Et 743 were characterized using gel elec-trophoresis. Surprisingly, Et 743 bends DNA toward the major groove, a unique feature among DNA-interactive agents that occupy the minor groove. Second, in order to gain further insight into the molecular basis behind the apparent sequence selectivity of Et 743, the stability and structure of Et 743 adducts at different target sequences were determined. On the basis of this data, the overall stability of the Et 743-DNA adducts was found to be governed by the DNA target sequence, where the inability of Et 743 to form optimum bonding networks with its optimum recognition sites leads to the formation of an unstable adduct. Consequently, the reaction of Et 743 with DNA is reversible, and the rate of the reverse reaction is a function of the target and flanking sequences.
The results from this study demonstrate that Et 743 differs from other DNA alkylating agents by its effects on DNA structure and sequence-dependent chemical stability. This information provides important insight into the underlying mechanisms for its unique pro-file of antitumor activity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Borowy-Borowski, H., Lipman, R., Chowdary, D., and Tomasz, M., 1990, Duplex oligodeoxyribonucleotides cross-linked by mitomycin C at a single site: synthesis, properties, and cross-link reversibility, Biochemistry 29: 2992–2999.
Bowman, A., Twelves, C., Hoekman, K., Simpson, A., Smyth, J., Vermorken, J., Höppener, F., Beijnen, J., Vega, E., Jimeno, J., and Hanauske, A.-R., 1998, Phase I clinical and pharmacokinetic (PK) study of ecteinascidin-743 (Et-743) given as a one-hour infusion every 21 days, Ann. Oncol. 9 (suppl. 2):119.
Corey, E. J., Gin, D. Y., and Kania, R. S., 1996, Enantioselective total synthesis of ecteinascidin 743, J. Am. Chem. Soc. 118: 9202–9203.
Cvitkovic, E., Mekranter, B., Taamma, A., Goldwasser, F., Beijnen, J. H., Jimeno, J., Riofrio, M., Vega, E., Misset, J. L., and Hop, P., 1998, Ecteinascidin-743 (Et-743) 24-hour continuous intravenous infusion (CI) phase I study in solid tumors (ST) patients, Ann. Oncol. 9 (suppl. 2):119.
D’Incalci, M., 1999, Mode of action of ecteinascidin-743 (Et-743), in AACR-NCI-EORTC International Conference, p. 3872, Washington, D.C.
Gaucheron, F., Malinge, J. M., Blacker, A. J., Lehn, J. M., and Leng, M., 1991, Possible catalytic activity of DNA in the reaction between the antitumor drug cis-diamminedichloroplatinum(II) and the intercalator N-methyl-2,7-diazapyrenium, Proc. Natl. Acad. Sci. U.S.A. 88: 3516–3519.
Jimeno, J. M., Faircloth, G., Cameron, L., Meely, K., Vega, E., Gomez, A., Sousa-Faro, J. M. F., and Rinehart, K., 1996, Progress in the acquisition of new marine-derived anticancer compounds: development of the ecteinascidin-743 (Et 743), Drugs Future 21: 1155–1165.
Jin, S., Gorfajn, B., Faircloth, G., and Scotto, K. W., 2000, Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation, Proc. Natl. Acad. Sci. U.S.A. 97: 6775–6779.
Koo, H.-S., and Crothers, D. M., 1988, Calibration of DNA curvature and a unified de-scription of sequence-directed bending, Proc. Natl. Acad. Sci. U.S.A. 85: 1763–1767.
Koo, H.-S., Wu, H. M., and Crothers, D. M., 1986, DNA bending at adenine-thymine tract, Nature 230: 501–506.
Lee, C.-S., Sun, D., Kizu, R., and Hurley, L. H., 1991, Determination of the structural features of (+)-CC-1065 that are responsible for bending, winding, and stiffening of DNA, Chem. Res. Toxicol. 4: 203–213.
Martinez, E. J., Owa, T., Schreiber, S. L., and Corey, E. J., 1999, Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743, Proc. Natl. Acad. Sci. U.S.A. 96: 3496–3501.
Moore, B. M., II, Seaman, F. C., and Hurley, L. H., 1997, NMR-based model of an ecteinascidin 743-DNA adduct, J. Am. Chem. Soc. 119: 5475–5476.
Moore, B. M., II, Seaman, F. C., Wheelhouse, R. T., and Hurley, L. H., 1998, Mechanism for the catalytic activation of ecteinascidin 743 and its subsequent alkylation of guanine N2, J. Am. Chem. Soc. 120:2490–2491.
Pommier, Y., Kohlhagen, G., Bailly, C., Waring, M., Mazumder, A., and Kohn, K. W., 1996, DNA sequence-and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata, Biochemistry 35: 13303–13309.
Remers, W. A., 1988, The Chemistry of Antitumor Antibiotics, Volume 2, John Wiley and Sons, Inc., New York.
Rinehart, K. L., Holt, T. G., Fregeau, N. L., Stroh, J. G., Keifer, P. A., Sun, F., Li, L. H., and Martin, D. G., 1990, Ecteinascidins 729, 743, 745,7 59A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata, J. Org. Chem. 55: 4512–4515.
Rink, S. M., and Hopkins, P. B., 1995, A mechlorethamine-induced DNA interstrand cross-link bends duplex DNA, Biochemistry 34: 1439–1445.
Rink, S. M., Lipman, R., Alley, S. C., Hopkins, P. B., and Tomasz, M., 1996, Bending of DNA by the mitomycin C-induced, GpG intrastrand cross-link, Chem. Res. Toxicol. 9: 382–389.
Sakai, R., Jares-Erijman, E. A., Manzanares, I., Silva Elipe, M. V., and Rinehart, K. L., 1996, Ecteinascidins: putative biosynthetic precursors and absolute stereochemistry, J. Am. Chem. Soc. 118: 9017–9023.
Seaman, F. C., and Hurley, L. H., 1998, Molecular basis for the DNA sequence selectivity of ecteinascidin 736 and 743: evidence for the dominant role of direct readout via hydrogen bonding, J. Am. Chem. Soc. 120: 13028–13041.
Takebayashi, Y., Pourquier, P., Yoshida, A., Kohlhagen, G., and Pommier, Y., 1999, Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove, Proc. Natl. Acad. Sci. U.S.A. 96: 7196–7210.
Takebayashi, Y., Goldwasser, F., Urasaki, Y., Kohlhagen, G., and Pommier, Y., 2000, Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression, Clinical Cancer Research, submitted.
Villalona-Calero, M., Eckhardt, S. G., Weiss, G., Campbell, E., Hidalgo, M., Kraynak, M., Beijnen, J., Jimeno, J., Von Hoff, D., and Rowinsky, E., 1998, A phase I and pharmacokinetic study of Et-743, a novel DNA minor groove binder of marine origin, administered as a 1-hour infusion daily x5 days, Ann. Oncol. 9 (suppl. 2):119.
Warpehoski, M. A., Harper, D. E., Mitchell, M. A., and Monroe, T. J., 1992, Reversibility of the covalent reaction of CC-1065 and analogues with DNA, Biochemistry 31: 2502–2508.
Zahn, K., and Blattner, F. R., 1987, Direct evidence for DNA bending at the lambda replication origin, Science 236: 416–422.
Zewail-Foote, M., and Hurley, L. H., 1999, Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove, J. Med. Chem. 42: 2493–2497.
Zinkel, S. S., and Crothers, D. M., 1987, DNA bend direction by phase sensitive detection, Nature 328:178–181.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hurley, L.H., Zewail-Foote, M. (2001). The Antitumor Agent Ecteinascidin 743: Characterization of Its Covalent Dna Adducts and Chemical Stability. In: Dansette, P.M., et al. Biological Reactive Intermediates VI. Advances in Experimental Medicine and Biology, vol 500. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0667-6_46
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0667-6_46
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5185-6
Online ISBN: 978-1-4615-0667-6
eBook Packages: Springer Book Archive